NCT06730022

Dermacyte® Liquid for Treatment of Cutaneous Ulcers and Wounds

• Status: Available
• Phase: —
• Study type: Expanded Access
• Enrollment: —
• Sponsor: Merakris Therapeutics · Industry
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

The objective of this study is to make Dermacyte Liquid available on an expanded access basis to treat cutaneous ulcers and wounds refractory to initial treatment or that do not have adequate alternative treatments. Minimal data will be collected to evaluate the efficacy and safety of Dermacyte Liquid.

Detailed description

The primary purpose is to provide expanded access of Dermacyte Liquid to subjects who have serious cutaneous ulcers and wounds (e.g., ulcers related to diabetes mellitus, venous insufficiency, complications of systemic sclerosis or rheumatic disease; decubitus ulcers, burns, acute trauma, wound dehiscence, ischemic ulcers, and mixed etiology ulcers). Eligible subjects must have a high likelihood of significant morbidity, loss of quality of life, potential amputation, or mortality without efficacious treatment. As there are many types of patients who may be enrolled, study results will not have statistical significance.

Conditions

• Cutaneous Ulcer
• Diabetic Ulcer
• Surgical Wound Dehiscence
• Burns - Multiple
• Pressure Ulcers
• Mixed Ulcer
• Ischemic Ulcer

Interventions

Type	Name	Description
DRUG	MTX-001 (Dermacyte Liquid)	Repeat dose subcutaneous drug injection for the treatment of serious chronic wounds.

Timeline

• First posted: 2024-12-12
• Last updated: 2025-02-25

Locations

1 site across 1 country: United States